Drug intelligence / Profile preview

bupropion + fluoxetine

Development stage
Preclinical
Lead developer
GSK
Modality
Small Molecules
Administration
Oral
01

Overview

Bupropion + fluoxetine is a combination of two antidepressants with different mechanisms of action. Bupropion (Wellbutrin) is a norepinephrine-dopamine reuptake inhibitor (NDRI), while fluoxetine (Prozac) is a selective serotonin reuptake inhibitor (SSRI). This dual-mechanism approach targets different neurotransmitter systems that regulate mood. The combination is sometimes used for treatment-resistant depression or when a patient has had an incomplete response to SSRI therapy alone, potentially providing enhanced antidepressant efficacy and mitigating SSRI-associated sexual dysfunction. However, it requires careful medical supervision due to potential interactions and carries significant risks including increased seizure potential (bupropion lowers the seizure threshold) and possible serotonin syndrome.

Other names
fluoxetine + amfebutamone
02

Targets

α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on bupropion + fluoxetine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bupropion + fluoxetine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call